IMMU Immunomedics, Inc.

4.04
+0  (0%)
Previous Close 4.04
Open 3.96
Price To book 0.00
Market Cap 428.01M
Shares 105,942,000
Volume 3,432,616
Short Ratio 10.00
Av. Daily Volume 1,676,820

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data due December 9, 2016 at SABCS. Announced December 27, 2016 that enrollment has met enrollment goal - Phase 3 to be initiated early 2017. BLA filing due mid-2017.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus

Latest News

  1. IMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers
  2. Thursday’s Biggest Biopharma Winners
  3. Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation
  4. venBio Sends Letter to Immunomedics Stockholders
  5. venBio Responds to Immunomedics Announcement
  6. Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors
  7. IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
  9. IMMUNOMEDICS ANNOUNCES INVESTOR R&D DAY ON JANUARY 18, 2017
  10. Immunomedics Announces Investor R&D Day on January 18, 2017
  11. Immunomedics Completes Enrollment In Cancer Drug Study
  12. IMMUNOMEDICS ANNOUNCES ACHIEVEMENT OF PATIENT ENROLLMENT INTO SINGLE-ARM PHASE 2 STUDY WITH SACITUZUMAB GOVITECAN (IMMU-132) IN TRIPLE-NEGATIVE BREAST CANCER
  13. Immunomedics Announces Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer
  14. IMMUNOMEDICS AWARDED ADDITIONAL INTELLECTUAL PROPERTY PROTECTION FOR IMMU-140, AN ANTIBODY-DRUG CONJUGATE WITH DUAL-THERAPEUTIC POTENTIAL
  15. Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential
  16. ETFs with exposure to Immunomedics, Inc. : December 21, 2016
  17. IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  18. Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers